Cyclandelate

• CAT Number: A000719
• CAS Number: 456-59-7
• Molecular Formula: C17H24O3
• Molecular Weight: 276.37
• Purity: ≥95%
• Synonyms: 456-59-7; Cyclolyt; Cyclomandol; Cyclospasmol; Ciclandelato
• Storage: -20°C
• InChI: 1S/C17H24O3/c1-12-9-14(11-17(2,3)10-12)20-16(19)15(18)13-7-5-4-6-8-13/h4-8,12,14-15,18H,9-11H2,1-3H3
• InChIKey: WZHCOOQXZCIUNC-UHFFFAOYSA-N
• SMILES: CC1CC(CC(C1)(C)C)OC(=O)C(C2=CC=CC=C2)O

Cyclandelate is a direct-acting smooth muscle relaxant vasodilator used in the treatment of claudication, arteriosclerosis and Raynaud/’s disease. It is also used to treat nighttime leg cramps, and has been investigated for its effect against migraine. It is orally administered.

Reference

1: Diener HC, Krupp P, Schmitt T, Steitz G, Milde K, Freytag S. Cyclandelate in
the prophylaxis of migraine: a placebo-controlled study. Cephalalgia. 2001
Feb;21(1):66-70. PubMed PMID: 11298666.

2: Weyer G, Eul A, Milde K, Wierich W, Herrmann WM. Cyclandelate in the treatment
of patients with mild to moderate primary degenerative dementia of the Alzheimer
type or vascular dementia: experience from a placebo controlled multi-center
study. Pharmacopsychiatry. 2000 May;33(3):89-97. PubMed PMID: 10855459.

3: Siniatchkin M, Gerber WD, Vein A. Clinical efficacy and central mechanisms of
cyclandelate in migraine: a double-blind placebo-controlled study. Funct Neurol.
1998 Jan-Mar;13(1):47-56. PubMed PMID: 9584874.

4: Hester TO, Theilman G, Green W, Jones RO. Cyclandelate in the management of
tinnitus: a randomized, placebo-controlled study. Otolaryngol Head Neck Surg.
1998 Mar;118(3 Pt 1):329-32. PubMed PMID: 9527112.

5: Schellenberg R, Todorova A, Wedekind W, Schober F, Dimpfel W. Pathophysiology
and psychopharmacology of dementia–a new study design. 2. Cyclandelate
treatment–a placebo-controlled double-blind clinical trial. Neuropsychobiology.
1997;35(3):132-42. PubMed PMID: 9170118.

6: Diener HC, Föh M, Iaccarino C, Wessely P, Isler H, Strenge H, Fischer M,
Wedekind W, Taneri Z. Cyclandelate in the prophylaxis of migraine: a randomized,
parallel, double-blind study in comparison with placebo and propranolol. The
Study group. Cephalalgia. 1996 Oct;16(6):441-7. PubMed PMID: 8902255.

7: Gerber WD, Schellenberg R, Thom M, Haufe C, Bölsche F, Wedekind W,
Niederberger U, Soyka D. Cyclandelate versus propranolol in the prophylaxis of
migraine–a double-blind placebo-controlled study. Funct Neurol. 1995
Jan-Feb;10(1):27-35. PubMed PMID: 7649498.

8: Dimpfel W, Schober F, Wedekind W, Kleinbloesem C, Coors C. [Evidence of a
pharmacokinetic-pharmacodynamic relationship between pharmaco-EEG in healthy
subjects after administration of cyclandelate]. Arzneimittelforschung. 1994
Sep;44(9):999-1004. German. PubMed PMID: 7986255.

9: White DA, Heffron F, Knight D, Salter AM. The effects of two acylcoenzyme A:
cholesterol acyltransferase (ACAT) inhibitors, cyclandelate and a
non-hydrolysable ether analogue, benzyl3,3,5-trimethylcyclohexanol on low density
lipoprotein metabolism in macrophages and hepatocytes. Biochem Pharmacol. 1994
Aug 30;48(5):915-22. PubMed PMID: 8093104.

10: Kitajima A, Yoshii K, Komatsu H, Ishimitsu S, Okada S. [The Cyclandelate
Reference Standard (Control 931) of the National Institute of Health Sciences].
Eisei Shikenjo Hokoku. 1994;(112):185-7. Japanese. PubMed PMID: 8854927.